Indications and uses
for relief of occasional sleeplessness when associated with minor aches and pains helps you fall asleep and stay asleep
for relief of occasional sleeplessness when associated with minor aches and pains helps you fall asleep and stay asleep
do not take more than directed adults and children 12 years and over: take 2 capsules at bedtime do not take more than 2 capsules in 24 hours
each capsule contains: potassium 20 mg read all warnings and directions before use. Keep carton. store at 20º-25ºC (68º-77ºF) protect from light avoid excessive heat above 40ºC (104ºF)
Diphenhydramine hydrochloride 25 mg
Solubilized ibuprofen equal to 200 mg ibuprofen (NSAID)*
(present as the free acid and potassium salt)
*nonsteroidal anti-inflammatory drug
Nighttime sleep-aid
Pain reliever
Allergy alert: Ibuprofen may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include:
If an allergic reaction occurs, stop use and seek medical help right away.
Stomach bleeding warning: This product contains a nonsteroidal anti-inflammatory drug (NSAID), which may cause severe stomach bleeding. The chance is higher if you
ask a health professional before use. It is especially important not to use ibuprofen during the last 3 months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
In case of overdose, get medical help or contact a Poison Control Center right away.
anidrisorb, D&C red no. 33, FD&C blue no. 1, gelatin, hydrolysed gelatin, medium chain triglyceride, opacode white ink, polyethylene glycol 600, potassium hydroxide, purified water.
Ingredients of opacode white ink: lecithin (soya), n-butyl alcohol, purified water, shellac glaze in ethanol, simethicone and titanium dioxide.
Call 1-800-426-9391 8:30 AM-4:00 PM ET, Monday-Friday
QUALITY
PLUS
NDC 50844-611-19
†Compare to the
active ingredients in
Advil® PM LIQUI-GELS®
IBUPROFEN PM
SOFTGELS
Ibuprofen 200 mg / Diphenhydramine HCl 25 mg
Pain Reliever (NSAID) / Nighttime Sleep-Aid
SEE NEW WARNINGS INFORMATION
8 Softgels**
**Liquid Filled Capsules
†This product is not manufactured or distributed by
Pfizer Consumer Healthcare, owner of the registered
trademark Advil® PM LIQUI-GELS®.
50844 ORG111261119
Product of India
Distributed by
LNK INTERNATIONAL, INC.
60 Arkay Drive, Hauppauge, NY 11788
USA
TAMPER EVIDENT: DO NOT USE IF CARTON IS OPENED OR IF BLISTER UNIT IS TORN, BROKEN OR SHOWS ANY SIGNS OF TAMPERING

| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| DIPHENHYDRAMINE HYDROCHLORIDE | ACTIVE INGREDIENT | TC2D6JAD40 | 2 | |
| IBUPROFEN | ACTIVE INGREDIENT | WK2XYI10QM | 2 | |
| DIPHENHYDRAMINE | ACTIVE MOIETY | 8GTS82S83M | 2 | |
| IBUPROFEN | ACTIVE MOIETY | WK2XYI10QM | 2 | |
| FD&C BLUE NO. 1 | INACTIVE INGREDIENT | H3R47K3TBD | 2 | |
| GELATIN | INACTIVE INGREDIENT | 2G86QN327L | 2 | |
| LECITHIN, SOYBEAN | INACTIVE INGREDIENT | 1DI56QDM62 | 2 | |
| MEDIUM-CHAIN TRIGLYCERIDES | INACTIVE INGREDIENT | C9H2L21V7U | 2 | |
| POLYETHYLENE GLYCOL 600 | INACTIVE INGREDIENT | NL4J9F21N9 | 2 | |
| POTASSIUM HYDROXIDE | INACTIVE INGREDIENT | WZH3C48M4T | 2 | |
| SHELLAC | INACTIVE INGREDIENT | 46N107B71O | 2 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 50844-611 | 50844-611-19 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| DIPHENHYDRAMINE HYDROCHLORIDE | TC2D6JAD40 | ACTIB |
| IBUPROFEN | WK2XYI10QM | ACTIB |
| FD&C BLUE NO. 1 | H3R47K3TBD | IACT |
| GELATIN, UNSPECIFIED | 2G86QN327L | IACT |
| MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | IACT |
| POLYETHYLENE GLYCOL 600 | NL4J9F21N9 | IACT |
| POTASSIUM HYDROXIDE | WZH3C48M4T | IACT |
| WATER | 059QF0KO0R | IACT |
| D&C RED NO. 33 | 9DBA0SBB0L | IACT |
| SORBITOL | 506T60A25R | IACT |
| SORBITAN | 6O92ICV9RU | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| POTASSIUM HYDROXIDE | POTASSIUM HYDROXIDE | WZH3C48M4T | GEL / TOPICAL | 3 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | ELIXIR / ORAL | NA | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | CAPSULE / ORAL | 4771 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | GUM, CHEWING / BUCCAL | 182 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SOLUTION / DENTAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SOAP / TOPICAL | 1 %w/w | ||
| POTASSIUM HYDROXIDE | POTASSIUM HYDROXIDE | WZH3C48M4T | SOLUTION / ORAL | ADJ PH | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, ORALLY DISINTEGRATING / ORAL | 6 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | SUSPENSION / ORAL | 10170 mg | ||
| POTASSIUM HYDROXIDE | POTASSIUM HYDROXIDE | WZH3C48M4T | AEROSOL, FOAM / TOPICAL | ADJ PH | ||
| GELATIN | GELATIN | 2G86QN327L | TABLET, CHEWABLE / ORAL | 24 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SUPPOSITORY / VAGINAL | NA | ||
| SHELLAC | SHELLAC | 46N107B71O | TABLET, EXTENDED RELEASE / ORAL | 213.24 mg | ||
| GELATIN | GELATIN | 2G86QN327L | SOLUTION / INTRAVENOUS | 34.8 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | INSERT, EXTENDED RELEASE / OPHTHALMIC | 0.4 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SYSTEM / TOPICAL | 420 mg | ||
| SHELLAC | SHELLAC | 46N107B71O | TABLET / ORAL | 112 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SUSPENSION / ORAL | 113 mg | ||
| GELATIN | GELATIN | 2G86QN327L | INJECTION, POWDER, FOR SUSPENSION / INTRAMUSCULAR | 2 mg | ||
| POTASSIUM HYDROXIDE | POTASSIUM HYDROXIDE | WZH3C48M4T | CAPSULE / ORAL | 172 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, LIQUID FILLED / ORAL | 0.08 mg | ||
| SHELLAC | SHELLAC | 46N107B71O | CAPSULE, DELAYED RELEASE / ORAL | 1 mg | ||
| GELATIN | GELATIN | 2G86QN327L | INJECTION / INTRAMUSCULAR | 16 %w/v | ||
| POTASSIUM HYDROXIDE | POTASSIUM HYDROXIDE | WZH3C48M4T | CAPSULE, DELAYED RELEASE / ORAL | 5 mg | ||
| SHELLAC | SHELLAC | 46N107B71O | SUSPENSION / ORAL | 3 mg/1ml | ||
| SHELLAC | SHELLAC | 46N107B71O | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | SPRAY, METERED / SUBLINGUAL | 110 mg | ||
| GELATIN | GELATIN | 2G86QN327L | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| GELATIN | GELATIN | 2G86QN327L | CAPSULE, COATED / ORAL | 288 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CREAM / TOPICAL | 0.01 %w/w | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | PASTE / DENTAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / ORAL | 2 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / ORAL | 2 mg | ||
| POTASSIUM HYDROXIDE | POTASSIUM HYDROXIDE | WZH3C48M4T | SOLUTION / TOPICAL | 14.02 %w/w | ||
| GELATIN | GELATIN | 2G86QN327L | GUM, CHEWING / BUCCAL | 102 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | LOTION / TOPICAL | 7 %w/w | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET / ORAL | 232 mg | ||
| SHELLAC | SHELLAC | 46N107B71O | CAPSULE / ORAL | 34.48 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, DELAYED RELEASE / ORAL | 2 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | TABLET, EXTENDED RELEASE / ORAL | 0.37 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE / ORAL | 72 mg | ||
| SHELLAC | SHELLAC | 46N107B71O | TABLET, COATED / ORAL | 30 mg | ||
| POTASSIUM HYDROXIDE | POTASSIUM HYDROXIDE | WZH3C48M4T | PASTILLE / ORAL | ADJ PH | ||
| GELATIN | GELATIN | 2G86QN327L | TABLET / SUBLINGUAL | 19 mg | ||
| SHELLAC | SHELLAC | 46N107B71O | TABLET, DELAYED RELEASE / ORAL | 8 mg | ||
| GELATIN | GELATIN | 2G86QN327L | PASTE / DENTAL | 252 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM / BUCCAL | 3 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, SUGAR COATED / ORAL | NA | ||
| POLYETHYLENE GLYCOL 600 | POLYETHYLENE GLYCOL 600 | NL4J9F21N9 | CAPSULE, LIQUID FILLED / ORAL | 1584 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 42 mg | ||
| POLYETHYLENE GLYCOL 600 | POLYETHYLENE GLYCOL 600 | NL4J9F21N9 | TABLET, EXTENDED RELEASE / ORAL | 2.5 mg | ||
| GELATIN | GELATIN | 2G86QN327L | SYRUP / ORAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | LOTION / TOPICAL | NA | ||
| GELATIN | GELATIN | 2G86QN327L | PASTILLE / ORAL | 143 mg | ||
| GELATIN | GELATIN | 2G86QN327L | TABLET / ORAL | 46 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, EXTENDED RELEASE / ORAL | 90 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | SPRAY / TOPICAL | 540 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | d4dbc9d85df4… | ||
| 2026-10-15 13:18:30 | 2026-09 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | c2088c7a36db… | ||
| 2026-09-14 22:38:34 | 2026-08 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A200888-001 | IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | CAPSULE / ORAL | 2012-03-05 | 3bdfa0b2c4d7… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| d086690c-8dce-4483-baa6-c301b735c9d4 | 3a5d7a29-d5ae-4c94-9295-341cb10905a5 | 2022-06-27 | Warnings | 3a5d7a29-d5ae-4c94-9295-341cb10905a5 |
Adverse event summaries are temporarily unavailable. Other product information remains available.